Selecta Biosciences, Inc. EV/Operating CF

EV/Operating CF of SELB for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/Operating CF growth rates and interactive chart. A valuation metric that measures the enterprise value of a company compared to its operating cash flow. Operating cash flow (OCF) is the amount of cash generated by a company's normal business operations. It can be different from reported net income due to accrual accounting, that is expenses and revenues are recognized differently than cash is received. The cash going in and out of the business is what ultimately determines its financial health, so it's one of the most important metrics to watch. A low EV/OCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/OCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current EV/Operating CF of Selecta Biosciences, Inc. is 6.41 (as of December 30, 2020)
  • EV/Operating CF for the quarter ending December 30, 2020 was 6.41 (a 24.7% increase compared to previous quarter)
  • Year-over-year quarterly EV/Operating CF decreased by -551.61%
  • Annual EV/Operating CF for 2020 was 6.41 (a -540.28% decrease from previous year)
  • Annual EV/Operating CF for 2019 was -1.46 (a 32.96% increase from previous year)
  • Annual EV/Operating CF for 2018 was -1.09 (a -58.79% decrease from previous year)
Visit stockrow.com/SELB for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/Operating CF of Selecta Biosciences, Inc.

Most recent EV/Operating CFof SELB including historical data for past 10 years.

Interactive Chart of EV/Operating CF of Selecta Biosciences, Inc.

Selecta Biosciences, Inc. EV/Operating CF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 6.41 5.14 6.41
2019 -1.46 -1.42 -1.38 -1.46
2018 -1.09
2017 -2.66 -8.95 -9.72 -8.32 -2.66
2016 -5.53 -6.59 0.92 -0.61 -5.53
2015 -0.61 -0.61 -0.61
2014 -0.61

Business Profile of Selecta Biosciences, Inc.

Sector: Healthcare
Industry: Biotechnology
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.